Medipure Pharmaceuticals |

In the News

Sep 23, 2020
COVID -19… A Physicians Perspective
I am writing this as Medical Director of Medipure Pharmaceuticals to provide some of my own perspective to this very unique period in our history. The WHO declared Covid-19 as a worldwide viral pandemic on March 11, 2020 and in our province (British Columbia) a province wide “state of emergency” was instituted a week later on March 18. Coronavirus disease is a novel infectious disease caused by severe acute respiratory syndrome coronavirus 2. This virus is in the same family as the virus that caused the significant SARS outbreak in 2002-2004.
Read More
Sep 22, 2020
Medipure Holdings Inc. Announces Publication of U.S. and International PCT Patent Application for MP20X, a Drug Formulation to Treat Anxiety and Depression
Medipure Holdings Inc. (“Medipure” or the “Company”), is pleased to announce the publication of U.S. patent applications 20200253947 and 20200253948 and the publication international PCT patent application (PCT/CA2020/050165) for MP20X. The published patents relate to pharmaceutical formulations for treating anxiety and depression, specifically, formulations that combine one or more than one cannabinoid receptor agonist and one or more than one serine hydrolase enzyme inhibitor as anxiolytic therapeutic product.
Read More
Jun 18, 2020
MEDIPURE FILES INTERNATIONAL APPLICATION UNDER WIPO's PATENT COORPORATION TREATY (PCT) FOR ANXIOLYTIC FORMULATIONS
Medipure Pharmaceuticals Inc., has filed patent applications and confirmed receipts with International Applications Under WIPO’s Patent Cooperation Treaty (PCT), an important step in providing intellectual and commercial protection for MP-20X as an endocannabinoid system-based prescription Anxiolytic medications.
Read More
Feb 16, 2019
The Medipure Newsletter - Q4 2018 Edition
Read our Q4 2018 Edition of the Company Newsletter
Read More
Feb 12, 2019
Medipure Announces Key Addition To Take Company To Next Stage Of Development
Medipure appoints Alan C. Mendelson as Corporate Secretary and Advisor to the Board of Directors.
Read More

Homepage

Mission

Significantly improve quality of patients' lives through development of safe and effective endocannabinoid-based therapeutics.

Vision

To be the leaders in need-driven endocannabinoid system-based prescription medication development.

Goal

To develop proprietary endocannabinoid system-based prescription drugs for targeted diseases by regulating specific molecular mechanisms.

Our Focus

Medipure Pharmaceuticals is a biopharmaceutical company conducting pioneering research in prescription pharmaceuticals. We are specifically focused on developing and marketing these propriety therapeutics for targeted diseases.

Pain Management
Affective disorders
Nausea and appetite
Palliative care
Oncology
Arthritis
Dermatology